1. Home
  2. CII vs EVO Comparison

CII vs EVO Comparison

Compare CII & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Capital and Income Fund Inc.

CII

Blackrock Capital and Income Fund Inc.

HOLD

Current Price

$24.70

Market Cap

841.0M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.57

Market Cap

994.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CII
EVO
Founded
2004
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
841.0M
994.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CII
EVO
Price
$24.70
$2.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
59.5K
28.6K
Earning Date
01-01-0001
04-08-2026
Dividend Yield
6.17%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.30
$2.31
52 Week High
$26.17
$4.42

Technical Indicators

Market Signals
Indicator
CII
EVO
Relative Strength Index (RSI) 48.30 37.20
Support Level $23.95 $2.32
Resistance Level $26.14 $3.82
Average True Range (ATR) 0.47 0.07
MACD -0.10 -0.03
Stochastic Oscillator 28.64 0.00

Price Performance

Historical Comparison
CII
EVO

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: